Listed pharmas weakened even in manufacturing-level profitability

Published: 2017-03-15 13:51:51

Updated: 2017-03-15 13:51:51

It was analyzed the listed pharmaceutical companies’ gross margin/sales ratio is getting weaker and weaker in not only sales, but manufacturing-level profitability.

According to the Yakup Shinmoon’s(www.yakup.com) analysis result of KOSPI and KOSDAQ listed pharmaceutical companies’ 2016 operating performance, their average gross margin/sales ratio was 37.6%.

The ratio was decreased by 2.6%p f...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.